Luke Versten, MPH

Senior Associate, New York

Why did you join Deallus?

Despite the promise inherent in the volume of breakthrough therapeutic innovations, challenging questions persist as to how these advances will be tested in research, regulatory, and marketplace contexts. I engage in work that reframes these challenges, raises implications, and enables stakeholders to navigate the complexities of a system defined by constant change. I feel the most rewarded in my work when I can drive product and portfolio level strategic assessments, convey the impact of the latest R&D breakthroughs, and contextualize opportunity across therapeutic landscapes to a variety of stakeholders.

I also chose Deallus because of the people. We’re all very bright on our own but we work well together as a team and that’s fun to be part of. Development is a real priority here and I like being part of that, whether it’s helping to train new joiners or getting coaching from the leadership that helps us improve.

Luke Versten Deallus Senior Associate

Background and experience

  • MPH, Epidemiology of Microbial Diseases, Yale University

  • BS, Biological Sciences, University of Chicago

Therapy area expertise

  • Immuno-oncology

  • Urology

  • NASH

  • Infectious Diseases/Virology

Deallus New York

Life outside of work

I love live music – I went to see Tame Impala recently at MSG. I also love exploring NYC. I like to travel – the next places in the US that are on my list are New England and the Pacific Northwest. I grew up outside Chicago so I am a Bears fan, which was fun last year but… less so this year.

Authored insight

Antimicrobial Resistance

Lack of innovation surrounding the development of new antibiotics has resulted in an alarming situation, given the rising threat of antimicrobial resistance (AMR). As a result, there is no single or straightforward way to combat AMR, nor to galvanize development of novel antibiotics. Although some positive measures have been introduced, further - and larger scale - action is needed. We take a look at what pharma and the larger healthcare industry needs to do in order to combat this looming threat.

Copay Accumulator Programs & Pharma

Dynamics between pharma and the market-based healthcare sector it serves have invariably been complex, with one of the biggest drivers of that complexity being effective management of patient demand and payer systems. The newest stratagem in this push and pull is the copay accumulator program, or CAP. We take a closer look at CAPs and how they might affect your brand in the near future.

People also viewed

We are always seeking other like-minded people who are as passionate about their work as we are, have a track record of demonstrating initiative, and are looking for a position where they can achieve their full potential.

Join us!

Join our team